ArticleIn vivo (Athens, Greece)

Four-weekly Low-dose Gemcitabine and Paclitaxel in Patients With Platinum-resistant Urothelial Cancer and Performance Status 2/3.

Kyohei Araki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.